Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.

Authors:
Rory Sheehan
Rory Sheehan
University College London bCamden Learning Disabilities Service
United Kingdom
Laura Horsfall
Laura Horsfall
University College London
London | United Kingdom
Andre Strydom
Andre Strydom
University College London
United Kingdom
David Osborn
David Osborn
University College London
London | United Kingdom
Kate Walters
Kate Walters
University College London
United Kingdom
Angela Hassiotis
Angela Hassiotis
University College London
United Kingdom

BMJ Open 2017 Aug 3;7(8):e017406. Epub 2017 Aug 3.

Division of Psychiatry, University College London, London, UK.

Objectives: To measure the incidence of movement side effects of antipsychotic drugs in adults with intellectual disability and compare rates with adults without intellectual disability.

Design: Cohort study using data from The Health Improvement Network.

Setting: UK primary care.

Participants: Adults with intellectual disability prescribed antipsychotic drugs matched to a control group of adults without intellectual disability prescribed antipsychotic drugs.

Outcome Measures: New records of movement side effect including acute dystonias, akathisia, parkinsonism, tardive dyskinaesia and neuroleptic malignant syndrome.

Results: 9013 adults with intellectual disability and a control cohort of 34 242 adults without intellectual disability together contributed 148 709 person-years data. The overall incidence of recorded movement side effects was 275 per 10 000 person-years (95% CI 256 to 296) in the intellectual disability group and 248 per 10 000 person-years (95% CI 237 to 260) in the control group. The incidence of any recorded movement side effect was significantly greater in people with intellectual disability compared with those without (incidence rate ratio 1.30, 95% CI 1.18 to 1.42, p<0.001, after adjustment for potential confounders), with parkinsonism and akathisia showing the greatest difference between the groups. Neuroleptic malignant syndrome, although occurring infrequently, was three times more common in people with intellectual disability-prescribed antipsychotic drugs (incidence rate ratio 3.03, 95% CI 1.26 to 7.30, p=0.013). Differences in rates of movement side effects between the groups were not due to differences in the proportions prescribed first and second-generation antipsychotic drugs.

Conclusions: This study provides evidence to substantiate the long-held assumption that people with intellectual disability are more susceptible to movement side effects of antipsychotic drugs. Assessment for movement side effects should be integral to antipsychotic drug monitoring in people with intellectual disability. Regular medication review is essential to ensure optimal prescribing in this group.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2017-017406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724123PMC
August 2017
7 Reads

Publication Analysis

Top Keywords

intellectual disability
32
adults intellectual
28
movement side
20
antipsychotic drugs
12
side effects
12
intellectual
9
control group
8
prescribed antipsychotic
8
person-years 95%
8
incidence recorded
8
recorded movement
8
000 person-years
8
disability prescribed
8
cohort study
8
drugs adults
8
disability
8
effects antipsychotic
8
adults
7
movement
5
side including
4

Altmetric Statistics

Similar Publications

Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.

BMJ 2015 Sep 1;351:h4326. Epub 2015 Sep 1.

Research Department of Primary Care and Population Health, University College London (Royal Free Campus), London NW3 2PF, UK.

Objectives: To describe the incidence of recorded mental illness and challenging behaviour in people with intellectual disability in UK primary care and to explore the prescription of psychotropic drugs in this group.

Design: Cohort study.

Setting: 571 general practices contributing data to The Health Improvement Network clinical database. Read More

View Article
September 2015

Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.

BMJ Open 2016 12 5;6(12):e013116. Epub 2016 Dec 5.

Imperial College, London, UK.

Objectives: To determine the prevalence and quality of antipsychotic prescribing for people with intellectual disability (ID).

Design: A clinical audit of prescribing practice in the context of a quality improvement programme. Practice standards for audit were derived from relevant, evidence-based guidelines, including NICE. Read More

View Article
December 2016

Movement Disorders in Adults With Intellectual Disability and Behavioral Problems Associated With Use of Antipsychotics.

J Clin Psychopharmacol 2016 Aug;36(4):308-13

From the *Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht; †Altrecht Institute for Mental Health Care, Den Dolder; ‡Licht-Zorg, Psychiatric Care, Maarssen; §Behavioural Science Institute, Faculty of Social Sciences, Radboud University Nijmegen, Nijmegen; ∥GGZ Centraal, Department Innova, Amersfoort; and ¶Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, the Netherlands.

Background: Antipsychotic drugs are prescribed to approximately 30% to 40% of adults with intellectual disability (ID) and behavioral problems despite lack of evidence of effectiveness and potential adverse effects, including movement disorders.

Aims: The aim of this study was to examine the prevalence of movement disorders (dyskinesia, akathisia, dystonia, and parkinsonism) in in-patient adults with mild to borderline ID and behavioral problems associated with use of antipsychotics.

Methods: Prevalence of movement disorders was measured with a standardized protocol. Read More

View Article
August 2016

Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.

Am J Psychiatry 1991 Oct;148(10):1322-8

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962.

Objective: The authors' goal was to determine the prevalence of and risk factors for neuroleptic-induced movement disorders in a group of psychiatrically hospitalized children and adolescents.

Method: They evaluated the presence or absence of parkinsonism, tardive dyskinesia, and akathisia in 104 children and adolescents who were in residence in or admitted over a 6-month period to a state-operated child psychiatric center. They applied a standardized, structured assessment procedure used in research on adult and geriatric psychiatric patients and the mentally retarded. Read More

View Article
October 1991